MAXCYTE, INC. (Nasdaq:MXCT)

Health Care/Life Sciences • Biotechnology

CIK 1287098

Company

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Address
9713 Key West Avenue
Suite 400
Rockville, Maryland 20850

Employees
125

Stock Info

Close
$4.1000

Day Range
4.0300 - 4.6300

52 Week Range
2.4500 - 5.5450

Average volume
803.42K

Short Interest
3.17M (02/15/24)

% of Float Shorted
3.48%

Market Cap
$484.33M

Revenue
$44.26M

Net Income
-$23.57M

2020 Sales Growth
N/A

Rev. per Employee
$304.38K

P/E Ratio
N/A

EPS
-$0.3637

Yield
N/A

Dividend
N/A

Ex-Dividend Date
N/A

Key Executives

Board Of Directors

President, Chief Executive Officer & Director
Maher Masoud

Independent Chairman
Richard H Douglas PhD

Independent Non-Executive Director
Rekha Hemrajani MBA

Independent Non-Executive Director
Yasir Baha Al-Wakeel MD

Independent Non-Executive Director
Arthur M Mandell MBA

Independent Non-Executive Director
Patrick J Balthrop Sr., MBA

Independent Non-Executive Director
Stanley C Erck MBA

Independent Non-Executive Director
William W Brooke

Independent Non-Executive Director
John Joseph Johnston MBA

SEC filings

Date	Form	Event
5 Sep, 2024	4
3 Sep, 2024	144
28 Aug, 2024	4
6 Aug, 2024	8-K
6 Aug, 2024	10-Q
5 Aug, 2024	4
30 Jul, 2024	4
10 Jul, 2024	4
1 Jul, 2024	4
27 Jun, 2024	144
24 Jun, 2024	4
20 Jun, 2024	144
13 Jun, 2024	4
13 Jun, 2024	4
13 Jun, 2024	4
13 Jun, 2024	4
13 Jun, 2024	4
13 Jun, 2024	4
13 Jun, 2024	4
13 Jun, 2024	4
12 Jun, 2024	8-K
10 Jun, 2024	4
7 May, 2024	10-Q
7 May, 2024	8-K
1 May, 2024	ARS
26 Apr, 2024	DEF 14A
28 Mar, 2024	4
25 Mar, 2024	SC 13G
19 Mar, 2024	4
19 Mar, 2024	4
19 Mar, 2024	4
12 Mar, 2024	8-K
12 Mar, 2024	10-K
5 Mar, 2024	8-K
4 Mar, 2024	3
28 Feb, 2024	4
26 Feb, 2024	144
14 Feb, 2024	SC 13G/A
14 Feb, 2024	SC 13G
13 Feb, 2024	SC 13G
1 Feb, 2024	SC 13G/A
30 Jan, 2024	4
26 Jan, 2024	8-K
26 Jan, 2024	SC 13G/A
8 Jan, 2024	8-K
4 Jan, 2024	4
28 Dec, 2023	4
11 Dec, 2023	8-K	CEO Change
6 Dec, 2023	4
1 Dec, 2023	4
29 Nov, 2023	144
29 Nov, 2023	4
17 Nov, 2023	SC 13G
16 Nov, 2023	4
14 Nov, 2023	144
8 Nov, 2023	8-K
8 Nov, 2023	10-Q
4 Oct, 2023	8-K
30 Aug, 2023	4
9 Aug, 2023	8-K
9 Aug, 2023	10-Q
28 Jul, 2023	4
12 Jul, 2023	4
10 Jul, 2023	144
28 Jun, 2023	4
26 Jun, 2023	144
23 Jun, 2023	8-K
23 Jun, 2023	4
23 Jun, 2023	4
23 Jun, 2023	4
23 Jun, 2023	4
23 Jun, 2023	4
23 Jun, 2023	4
23 Jun, 2023	4
23 Jun, 2023	4
15 Jun, 2023	4
10 May, 2023	10-Q
10 May, 2023	8-K
5 May, 2023	4
28 Apr, 2023	ARS
28 Apr, 2023	DEF 14A
12 Apr, 2023	4
12 Apr, 2023	4
7 Apr, 2023	4
7 Apr, 2023	4
4 Apr, 2023	4
4 Apr, 2023	4
30 Mar, 2023	4
28 Mar, 2023	3
28 Mar, 2023	4
28 Mar, 2023	8-K
21 Mar, 2023	4
21 Mar, 2023	4
21 Mar, 2023	4
21 Mar, 2023	4
21 Mar, 2023	4
21 Mar, 2023	4
21 Mar, 2023	4
15 Mar, 2023	8-K
15 Mar, 2023	10-K
6 Mar, 2023	8-K
14 Feb, 2023	SC 13G/A
13 Feb, 2023	SC 13G/A
3 Feb, 2023	4
3 Feb, 2023	4
31 Jan, 2023	SC 13G/A
10 Jan, 2023	SC 13G/A
5 Jan, 2023	4
5 Jan, 2023	4
6 Dec, 2022	4
2 Dec, 2022	144
1 Dec, 2022	8-K
1 Dec, 2022	4
1 Dec, 2022	144
1 Dec, 2022	3
30 Nov, 2022	144
22 Nov, 2022	144
21 Nov, 2022	144
18 Nov, 2022	144
17 Nov, 2022	144
16 Nov, 2022	144
10 Nov, 2022	144
9 Nov, 2022	10-Q
9 Nov, 2022	144
9 Nov, 2022	8-K
3 Nov, 2022	4
12 Oct, 2022	4
5 Oct, 2022	4
10 Aug, 2022	10-Q
10 Aug, 2022	8-K
14 Jul, 2022	S-8
8 Jul, 2022	4
8 Jul, 2022	4
8 Jul, 2022	4
8 Jul, 2022	4
8 Jul, 2022	4
8 Jul, 2022	4
8 Jul, 2022	4
6 Jul, 2022	4
30 Jun, 2022	8-K
26 May, 2022	DEF 14A
9 May, 2022	8-K
9 May, 2022	10-Q
29 Apr, 2022	10-K/A
12 Apr, 2022	8-K
29 Mar, 2022	4
29 Mar, 2022	4
29 Mar, 2022	4
29 Mar, 2022	4
29 Mar, 2022	4
22 Mar, 2022	8-K
22 Mar, 2022	10-K
17 Mar, 2022	3
15 Feb, 2022	SC 13G
11 Feb, 2022	SC 13G
4 Feb, 2022	SC 13G
24 Jan, 2022	8-K
23 Nov, 2021	4
16 Nov, 2021	4
16 Nov, 2021	4
16 Nov, 2021	4
16 Nov, 2021	4
16 Nov, 2021	4
10 Nov, 2021	8-K
10 Nov, 2021	10-Q
2 Nov, 2021	8-K
1 Oct, 2021	8-K
1 Oct, 2021	DEF 14A
17 Sep, 2021	8-K
13 Sep, 2021	10-Q
11 Aug, 2021	4
11 Aug, 2021	4
11 Aug, 2021	4
11 Aug, 2021	4
11 Aug, 2021	4
11 Aug, 2021	4
11 Aug, 2021	4
11 Aug, 2021	4
11 Aug, 2021	4
11 Aug, 2021	4
11 Aug, 2021	4
11 Aug, 2021	4
11 Aug, 2021	4
5 Aug, 2021	S-8
4 Aug, 2021	8-K
3 Aug, 2021	4
3 Aug, 2021	SC 13G
30 Jul, 2021	424B4	IPO completed
30 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	EFFECT
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	CERT
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	S-1MEF
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
29 Jul, 2021	3
27 Jul, 2021	8-A12B
27 Jul, 2021	CORRESP
27 Jul, 2021	CORRESP
26 Jul, 2021	S-1/A
9 Jul, 2021	CORRESP
9 Jul, 2021	S-1
8 Jul, 2021	UPLOAD
25 Jun, 2021	DRS/A
25 Jun, 2021	DRSLTR
10 Jun, 2021	UPLOAD
14 May, 2021	DRS

Last update:2024-03-06 13:23:42.185186

Sign Up to Subscribe

Interested in special situations?

Join Tickerverse

customize event filters
create watchlists, bookmarks
get email notifications for the latest special situations
browse and analyze public companies, executives and SEC filings

Tickerverse is a great way to find investment opportunities in corporate actions.

By signing up you agree to our Terms of Service and Privacy Policy.